Beyond Air to Participate in Two Upcoming Healthcare Investor Conferences
Beyond Air (NASDAQ: XAIR), a commercial stage medical device and biopharmaceutical company specializing in nitric oxide (NO) treatments, has announced its participation in two major healthcare investor conferences.
The company's Chairman and CEO Steve Lisi will attend the Roth 37th Annual Growth Stock Conference scheduled for March 16-18, 2025, in Laguna, CA, and the Jones Healthcare and Technology Innovation Conference taking place April 8-9, 2025, in Las Vegas, NV.
Interested parties can schedule one-on-one meetings with the company representatives through their respective bank representatives at either conference.
Beyond Air (NASDAQ: XAIR), un'azienda nel settore dei dispositivi medici e biopharmaceuticals in fase commerciale specializzata nei trattamenti a base di ossido nitrico (NO), ha annunciato la sua partecipazione a due importanti conferenze per investitori nel settore sanitario.
Il Presidente e CEO dell'azienda, Steve Lisi, parteciperà alla 37ª Conferenza Annuale sulle Azioni in Crescita di Roth, in programma dal 16 al 18 marzo 2025, a Laguna, CA, e alla Conferenza sull'Innovazione in Sanità e Tecnologia di Jones, che si svolgerà l'8 e 9 aprile 2025, a Las Vegas, NV.
Le parti interessate possono pianificare incontri individuali con i rappresentanti dell'azienda tramite i rispettivi rappresentanti bancari durante entrambe le conferenze.
Beyond Air (NASDAQ: XAIR), una empresa de dispositivos médicos y biofarmacéuticos en etapa comercial especializada en tratamientos con óxido nítrico (NO), ha anunciado su participación en dos importantes conferencias de inversores en el sector salud.
El Presidente y CEO de la empresa, Steve Lisi, asistirá a la 37ª Conferencia Anual de Acciones en Crecimiento de Roth, programada del 16 al 18 de marzo de 2025, en Laguna, CA, y a la Conferencia de Innovación en Salud y Tecnología de Jones, que tendrá lugar el 8 y 9 de abril de 2025, en Las Vegas, NV.
Las partes interesadas pueden programar reuniones uno a uno con los representantes de la empresa a través de sus respectivos representantes bancarios en cualquiera de las conferencias.
비욘드 에어 (NASDAQ: XAIR), 질산화물 (NO) 치료를 전문으로 하는 상업 단계의 의료 기기 및 생물 제약 회사가 두 개의 주요 의료 투자자 회의에 참여한다고 발표했습니다.
회사의 회장 겸 CEO인 스티브 리시는 2025년 3월 16일부터 18일까지 캘리포니아주 라구나에서 열리는 로스 제37회 연례 성장주식 회의와 2025년 4월 8일부터 9일까지 네바다주 라스베가스에서 열리는 존스 헬스케어 및 기술 혁신 회의에 참석할 예정입니다.
관심 있는 당사자는 각 회의에서 회사 대표와의 일대일 미팅을 은행 대표를 통해 예약할 수 있습니다.
Beyond Air (NASDAQ: XAIR), une entreprise de dispositifs médicaux et de biopharmaceutiques à un stade commercial spécialisée dans les traitements à base de monoxyde d'azote (NO), a annoncé sa participation à deux grandes conférences pour investisseurs dans le secteur de la santé.
Le Président et CEO de l'entreprise, Steve Lisi, assistera à la 37e Conférence Annuelle sur les Actions en Croissance de Roth prévue du 16 au 18 mars 2025 à Laguna, CA, ainsi qu'à la Conférence sur l'Innovation en Santé et Technologie de Jones, qui se déroulera les 8 et 9 avril 2025 à Las Vegas, NV.
Les parties intéressées peuvent programmer des réunions individuelles avec les représentants de l'entreprise via leurs représentants bancaires respectifs lors de chaque conférence.
Beyond Air (NASDAQ: XAIR), ein Unternehmen für medizinische Geräte und biopharmazeutische Produkte in der kommerziellen Phase, das sich auf Stickstoffmonoxid (NO) Behandlungen spezialisiert hat, hat seine Teilnahme an zwei bedeutenden Investorenkonferenzen im Gesundheitswesen angekündigt.
Der Vorsitzende und CEO des Unternehmens, Steve Lisi, wird an der 37. jährlichen Wachstumsaktienkonferenz von Roth, die vom 16. bis 18. März 2025 in Laguna, CA, stattfindet, sowie an der Jones Healthcare und Technologie Innovationskonferenz, die am 8. und 9. April 2025 in Las Vegas, NV, stattfindet, teilnehmen.
Interessierte Parteien können über ihre jeweiligen Bankvertreter Einzelgespräche mit den Unternehmensvertretern während beider Konferenzen planen.
- None.
- None.
GARDEN CITY, N.Y., March 06, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, will participate in the Roth 37th Annual Growth Stock Conference being held March 16-18, 2025 in Laguna, CA and the Jones Healthcare and Technology Innovation Conference being held April 8-9, 2025 in Las Vegas, NV.
| Roth 37th Annual Growth Stock Conference details: | |
| Format: | One-on-one meetings |
| Date(s): | Sunday, March 16 – Monday, March 17 |
| Participant: | Steve Lisi, Chairman & CEO, Beyond Air |
| Jones Healthcare and Technology Innovation Conference details: | |
| Format: | Fireside chat |
| Date: | Tuesday, April 8 |
| Participant: | Steve Lisi, Chairman & CEO, Beyond Air |
| Webcast link: | To be available at https://www.beyondair.net/news-events/events/ prior to event |
If you are interested in requesting a one-on-one meeting at either of the conferences, please contact your respective bank representative to schedule accordingly.
About Beyond Air®, Inc.
Beyond Air is a commercial stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received FDA approval for its first system, LungFit® PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. Beyond Air is currently advancing its other revolutionary LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19), and nontuberculous mycobacteria (NTM) among others. Also, the Company has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder (ASD) and other neurological disorders. Additionally, Beyond Cancer, Ltd., an affiliate of Beyond Air, is investigating ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting. For more information, visit www.beyondair.net.
About LungFit®*
Beyond Air’s LungFit is a cylinder-free, phasic flow generator and delivery system and has been designated as a medical device by the U.S. Food and Drug Administration (FDA). The ventilator compatible version of the device can generate NO from ambient air on demand for delivery to the lungs at concentrations ranging from 1 ppm to 80 ppm. The LungFit system could potentially replace large, high-pressure NO cylinders providing significant advantages in the hospital setting, including greatly reducing inventory and storage requirements, improving overall safety with the elimination of NO2 purging steps, and other benefits. LungFit can also deliver NO at concentrations at or above 80 ppm for potentially treating severe acute lung infections in the hospital setting (e.g. COVID-19, bronchiolitis) and chronic, refractory lung infections in the home setting (e.g. NTM). With the elimination of cylinders, Beyond Air intends to offer NO treatment in the home setting.
* Beyond Air’s LungFit PH is approved for commercial use only in the United States of America to treat term and near-term neonates with hypoxic respiratory failure. Beyond Air’s other LungFit systems are not approved for commercial use and are for investigational use only. Beyond Air is not suggesting NO use over 80 ppm or use at home.
About Nitric Oxide
Nitric Oxide is a powerful molecule, naturally synthesized in the human body, proven to play a critical role in a broad array of biological functions. In the airways, NO targets the vascular smooth muscle cells that surround the small resistance arteries in the lungs. Currently, exogenous inhaled NO is used in adult respiratory distress syndrome, post certain cardiac surgeries and persistent pulmonary hypertension of the newborn to treat hypoxemia. Additionally, NO is believed to play a key role in the innate immune system and in vitro studies suggest that NO possesses anti-microbial activity not only against common bacteria, including both gram-positive and gram-negative, but also against other diverse pathogens, including mycobacteria, viruses, fungi, yeast and parasites, and has the potential to eliminate multi-drug resistant strains.
CONTACTS:
Investor Relations contacts
Corey Davis, Ph.D.
LifeSci Advisors, LLC
Cdavis@lifesciadvisors.com
(212) 915-2577
FAQ
Which investor conferences will Beyond Air (XAIR) attend in Spring 2025?
How can investors schedule meetings with Beyond Air (XAIR) at the upcoming conferences?
What is Beyond Air's (XAIR) primary focus as a company?
Who will represent Beyond Air (XAIR) at the 2025 investor conferences?
